N-[[(3S)-3-AMINO-1-(5-ETHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3-PYRROLIDINYL]METHYL]-2,4-DIFLUORO-BENZAMIDE;(S)-N-[[3-Amino-1-(5-ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-3-yl]methyl]-2,4-difluorobenzamide;AKT inhibitor
(AKT protein kinase inhibitor);BenzaMide, N-[[(3S)-3-aMino-1-(5-ethyl-7H-pyrrolo[2,3-d]pyriMidin-4-yl)-3-pyrrolidinyl]Methyl]-2,4-difluoro-;PF-AKT400;Protein kinase B,PF-AKT400,Akt,inhibit,PKB,PF-AKT-400,PF AKT400,Inhibitor,PFAKT400;PF-AKT400, 10 mM in DMSO
PF-AKT400 is a potent, ATP-competitive, and selective Akt (Protein Kinase B) inhibitor used for:
- Inhibiting Akt signaling in cancer research;
- Reducing tumor growth in xenograft models of prostate carcinoma (PC3) and colorectal carcinoma (Colo205);
- Achieving significant tumor growth inhibition (TGI) as a single agent or in combination with Rapamycin;
- Serving as a pharmacological tool to study Akt pathway modulation in vitro and in vivo;
- Demonstrating dose-dependent inhibition of phospho-S6 and induction of Akt hyperphosphorylation in cellular and animal models.